Success Metrics

Clinical Success Rate

50.0%

Based on 3 completed trials

Completion Rate

50%(3/6)

Active Trials

0(0%)

Results Posted

100%(3 trials)

Terminated

3(50%)

Phase Distribution

Ph phase_3

17%

Ph phase_1

17%

Ph phase_2

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

1(16.7%)

Phase 2Efficacy & side effects

4(66.7%)

Phase 3Large-scale testing

1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(3)

Detailed Status

Terminated3

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (16.7%)

Phase 24 (66.7%)

Phase 31 (16.7%)

Trials by Status

terminated350%

completed350%

Recent Activity

0 active trials

Showing 5 of 6

terminatedphase_2

Tofacitinib for Treatment of Moderate COVID-19

NCT04415151

terminatedphase_2

Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK Study

NCT04768504

terminatedphase_2

Clinical Trials (6)

Showing 6 of 6 trials

NCT04415151Phase 2

Tofacitinib for Treatment of Moderate COVID-19

Terminated

NCT04768504Phase 2

Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK Study

Terminated

NCT04580277Phase 2

Tofacitinib For Treatment Of Chronic Pouchitis

Terminated

NCT04469114Phase 3

Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia

Completed

NCT01786668Phase 2

Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis

Completed

NCT01599377Phase 1

Tofacitinib Bioequivalence Study Comparing Tablets And Capsules

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6